

# HARMONY

## The HARMONY consortium

HARMONY is a European Network of Excellence that captures, integrates, analyzes and harmonizes big data from high-quality multidisciplinary sources with the purpose of unlocking valuable knowledge on various hematologic malignancies (HMs).



<p>51 partners</p> <ul style="list-style-type: none"> <li>44 participants (10 European countries)</li> <li>7 pharmaceutical companies (EFPIA)</li> </ul>	<p>HM disease areas with a high unmet need in adult and pediatric patients</p> <table border="0"> <tr> <td>MM</td> <td>multiple myeloma</td> <td>CLL</td> <td>chronic lymphocytic leukemia</td> </tr> <tr> <td>AML</td> <td>acute myeloid leukemia</td> <td>NHL</td> <td>Non-Hodgkin lymphoma</td> </tr> <tr> <td>ALL</td> <td>acute lymphoblastic leukemia</td> <td>MDS</td> <td>myelodysplastic syndrome</td> </tr> </table>	MM	multiple myeloma	CLL	chronic lymphocytic leukemia	AML	acute myeloid leukemia	NHL	Non-Hodgkin lymphoma	ALL	acute lymphoblastic leukemia	MDS	myelodysplastic syndrome
MM	multiple myeloma	CLL	chronic lymphocytic leukemia										
AML	acute myeloid leukemia	NHL	Non-Hodgkin lymphoma										
ALL	acute lymphoblastic leukemia	MDS	myelodysplastic syndrome										

## The HARMONY consortium big data platform

The HM-specific big data platform developed by HARMONY will enable the more rapid definition of promising treatment strategies, and prediction of adverse events likely to be associated with such strategies.



## The HARMONY consortium stakeholders

The project brings together key stakeholders in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical fields to:

